Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes

[1] Kolterman OG(2003)Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 3082-3089

[2] Buse JB(2008)Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 1240-1250

[3] Fineman MS(2010)Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 431-439

[4] Drucker DJ(2010)Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition Diabetes Care 33 1734-1737

[5] Buse JB(2010)Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents Diabetes Care 33 1300-1303

[6] Taylor K(2011)Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 13 348-356

[7] Bergenstal RM(2013)Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus J Diabetes Investig 4 53-61

[8] Wysham C(2013)Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects Br J Clin Pharmacol 75 979-989

[9] Macconell L(2010)Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study Cardiovasc Diabetol. 9 6-322

[10] Bunck MC(2010)Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women Am Heart J 159 e3-1310

[1] Kolterman OG(2003)Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 3082-3089

[2] Buse JB(2008)Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 1240-1250

[3] Fineman MS(2010)Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 431-439

[4] Drucker DJ(2010)Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition Diabetes Care 33 1734-1737

[5] Buse JB(2010)Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents Diabetes Care 33 1300-1303

[6] Taylor K(2011)Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 13 348-356

[7] Bergenstal RM(2013)Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus J Diabetes Investig 4 53-61

[8] Wysham C(2013)Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects Br J Clin Pharmacol 75 979-989

[9] Macconell L(2010)Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study Cardiovasc Diabetol. 9 6-322

[10] Bunck MC(2010)Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women Am Heart J 159 e3-1310